Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Philip L Tzou"'
Publikováno v:
PLoS ONE, Vol 17, Iss 3, p e0261045 (2022)
As novel SARS-CoV-2 variants with different patterns of spike protein mutations have emerged, the susceptibility of these variants to neutralization by antibodies has been rapidly assessed. However, neutralization data are generated using different a
Externí odkaz:
https://doaj.org/article/6a12b3be12da44eabbc2dc61b0e1a590
Autor:
Philip L Tzou, Sergei L Kosakovsky Pond, Santiago Avila-Rios, Susan P Holmes, Rami Kantor, Robert W Shafer
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0225352 (2020)
IntroductionAt low mutation-detection thresholds, next generation sequencing (NGS) for HIV-1 genotypic resistance testing is susceptible to artifactual detection of mutations arising from PCR error and APOBEC-mediated G-to-A hypermutation.MethodsWe a
Externí odkaz:
https://doaj.org/article/922bfe8898a34209a3e2a7783bf3025d
Autor:
Roger Paredes, Philip L Tzou, Gert van Zyl, Geoff Barrow, Ricardo Camacho, Sergio Carmona, Philip M Grant, Ravindra K Gupta, Raph L Hamers, P Richard Harrigan, Michael R Jordan, Rami Kantor, David A Katzenstein, Daniel R Kuritzkes, Frank Maldarelli, Dan Otelea, Carole L Wallis, Jonathan M Schapiro, Robert W Shafer
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0181357 (2017)
HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment guidelines evolve.An expert panel was created to provide recommendations for the update of the St
Externí odkaz:
https://doaj.org/article/1e4b1cc89b67468c95603cd7d02e4c37
Autor:
Kaiming Tao, Zachary A. Osman, Philip L. Tzou, Soo-Yon Rhee, Vineet Ahluwalia, Robert W. Shafer
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Large language models (LLMs) that can efficiently screen and identify studies meeting specific criteria would streamline literature reviews. Additionally, those capable of extracting data from publications would enhance knowledge
Externí odkaz:
https://doaj.org/article/644a26d55740400eb9522b8dba4a1b4f
Publikováno v:
AIDS Research and Human Retroviruses. 39:119-123
HIV-1 pol nucleotide ambiguities encoding amino acid mixtures occur commonly during population-based genotypic drug resistance testing. However, few studies have addressed the validity of sequences with fully ambiguous codons (FACs) containing codons
Autor:
Kaiming Tao, Soo-Yon Rhee, Philip L. Tzou, Zachary A. Osman, Sergei L. Kosakovsky Pond, Susan P. Holmes, Robert W. Shafer
Publikováno v:
Viruses; Volume 15; Issue 4; Pages: 992
Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia. Successful sequence interpretation will require examining new capsi
Autor:
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, John P.A. Ioannidis, Robert W. Shafer
SARS-CoV-2 Omicron variants contain many mutations in its spike receptor binding domain, the target of all authorized monoclonal antibodies (mAbs). Determining the extent to which Omicron variants reduced mAb susceptibility is critical to preventing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055c818f5e361d00358447bb1132a041
Autor:
Geoffrey S. Gottlieb, Charlotte Charpentier, Susan Holmes, Vicente Soriano, Robert W. Shafer, Philip L Tzou, Soo-Yon Rhee, Robert A. Smith, Nuno Taveira, Carmen de Mendoza, Dana N. Raugi, Diane Descamps
Publikováno v:
J Infect Dis
BackgroundHIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs).MethodsWe analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations (TSMs). Mutation prevalences were det
Autor:
Kaiming Tao, Robert W. Shafer, Janin Nouhin, Prasanna Jagannathan, Hector Bonilla, Philip L Tzou
Publikováno v:
Clinical Microbiology Reviews
SUMMARY The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antivira
Autor:
Philip L. Tzou, Kaiming Tao, Malaya K. Sahoo, Sergei L. Kosakovsky Pond, Benjamin A. Pinsky, Robert W. Shafer
Publikováno v:
Journal of Clinical Virology. 157:105323
Although most laboratories are capable of employing established protocols to perform full-genome SARS-CoV-2 sequencing, many are unable to assess sequence quality, select appropriate mutation-detection thresholds, or report on the potential clinical